THE TAPE
CAPR · Pharmaceutical Preparations · $482.6M

Capricor Therapeutics Inc

$8.30▼ −12.91%
Last close
Relative strength
38RS
of 99, against every stock▲ +37 on the month
Turning up
Turning
−73.3%
six months against Pharmaceutical Preparations
52-week range
−79.4%
from the high
$2.96$40.37
Setup
On no screen
No base, flag or squeeze in place tonight. What is and is not there
Tomorrow
Nov 17 · confirmed
No US GAAP filings to read.
Why it is on no screen

CAPR is off the screens on 3 checks.

A base has formed24.0 weeks, from 4.30 to 13.98.
Long enough to count24.0 weeks against 3 needed.
Shallow enough69.2% deep against 35% allowed.
Close to its pivot-40.6% from the pivot; listed down to -20%.
Relative strengthRS 38 against 70 needed.

Measured against the base-and-breakout thresholds. The other screens use their own numbers, so a name can miss here and still be a fair-looking chart.

Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year
Support and resistance
Support below
$8.21
-1.1% · tested 3× · last 35 sessions ago
Resistance above
$9.50
+14.5% · tested 3× · last 39 sessions ago

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

Capricor Therapeutics Inc is not on any of the screens right now. Its relative strength rating is 38, and it sits in Pharmaceutical Preparations.

Against its industry
TurningBehind its industry over six months, but ahead over one and three.
One month against its industry
+18.4%
Three months against its industry
+35.5%
Six months against its industry
-73.3%

Read against an equal-weighted index of Pharmaceutical Preparations, which is +10.9% against the S&P 500 over six months Partly aligned.

Peers
Catalyst roadmap
1
day
Earnings tomorrow
Nov 17, 2026
  1. Earningsconfirmedin 1d
    Quarterly earnings
    Nov 17, 2026
How it moves on earnings

On average 16.4% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business

No figures in US GAAP filings for this company. Most foreign listings report under international standards, which this does not read.

Tracked funds

Held by 1 of 46 tracked funds at the end of Q3 2026.

Last quarter: 1 bought new.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
A new options position openedOPTIONS · 2026-11-14
2026-12-11 10P: OI +2,360 on 2,844 volume, ~$1.2M in puts (+1 more strike)
Too few cases to judge yet (180 cases over 9 nights).
GappedTape · 2026-11-14
-6.9%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-11-13
-8.7%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Closed above its 20- and 50-day on heavy volumeTape · 2026-11-12
above 20d & 50d on 2.6x volume at 11.22
Mixed: stocks have outrun random stocks by 0.2% over three sessions, not consistently enough to call (1,668 cases over 60 nights). Against their own sector they have lagged by 0.7%.
GappedTape · 2026-11-12
+26.5%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Moved 5%+ up on earningsTape · 2026-11-12
+26.5% on earnings 2026-11-10
No measurable effect: stocks behave like random ones over the next three sessions (604 cases over 42 nights).
GappedTape · 2026-11-11
-9.9%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Earnings comingEvent · 2026-11-10
reports 2026-11-10 amc
No measurable effect: stocks behave like random ones over the next three sessions (2,970 cases over 40 nights).

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Capricor’s HOPE-3 Phase 3 Cardiac Results for Deramiocel Win American Heart Association Outstanding Research Award in Pediatric CardiologyGlobeNewswire Inc. · 8 days ago

Headlines link to the publisher. We do not host, summarise or rank them, and a headline appearing here is not a view about the company.

Insiders
Bought on the open market
0
Sold on the open market
6
$1,518,316 total

Sold: Krasney Karen, Bergmann Anthony.

Not counted above: 6 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-06-25 Krasney Karen · EVP, GENERAL COUNSELoption exercise24,100$76,638
2026-06-25 Krasney Karen · EVP, GENERAL COUNSELsell24,100$732,158
2026-06-25 Bergmann Anthony · CHIEF FINANCIAL OFFICERoption exercise24,100$76,638
2026-06-25 Bergmann Anthony · CHIEF FINANCIAL OFFICERsell24,100$732,158
2026-06-24 Krasney Karen · EVP, GENERAL COUNSELoption exercise400$1,272
2026-06-24 Krasney Karen · EVP, GENERAL COUNSELsell400$12,000
2026-06-24 Bergmann Anthony · CHIEF FINANCIAL OFFICERoption exercise400$1,272
2026-06-24 Bergmann Anthony · CHIEF FINANCIAL OFFICERsell400$12,000

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

What analysts expect
Strong buy1
Buy3
Hold6
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

Checking your subscription…

X-ray

No completed base to compare this one with yet.

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
Capricor Therapeutics Inc (CAPR) — The Tape